Multiomics Market Size, Share, Industry, Forecast and Outlook (2024-2031)

Global Multiomics Market is segmented By Type (Single Cell Multiomics, Bulk Multiomics) By Platform (Genomics, Epigenomics, Transcriptomics, Proteomics, Metabolomics, Microbiomics) By Application (Oncology, Cell Biology, Neurology, Immunology, Stem Cell Research) By End-Users (Hospitals & Diagnostic Laboratories, Academic Institutes, Research Institutes, Pharmaceutical & Biotech Companies, Others) and By Region (North America, Europe, South America, Asia Pacific, Middle East, and Africa) – Share, Size, Outlook, and Opportunity Analysis, 2024-2031

Market Overview

The Global Multiomics Market reached US$ YY million in 2023 and is expected to reach US$ YY million by 2031, growing at a CAGR of YY% during the forecast period 2022-2031.

Multiomics provides an integrated approach to power discovery across multiple levels of biology. Multiomics is defined as the fusion of technology and biology. By combining data from genomics, transcriptomics, epigenetics, and proteomics, researchers can achieve a more comprehensive understanding of molecular changes contributing to normal development, cellular response, and disease.

By integrating multi‐omics, one can filter out novel associations between biomolecules and disease phenotypes, identify relevant signaling pathways, and establish detailed biomarkers of disease.

Market Scope

For more details on this report - Request for Sample

Market Dynamics: Drivers & Restraints

The increased research and development and increased funding 

The increased research and development and increased approach to understanding the mechanisms in the cells and biological cycles are expected to drive market growth. The increased funding for carrying out the research is expected to drive the market growth. 

For instance, in September 2023, NIH awarded $50.3 million for multi-omics research on human health and disease. The award is funded jointly by NHGRI, the National Cancer Institute (NCI), and the National Institute of Environmental Health Sciences (NIEHS).

Additionally, in May 2023, MultiOmic Health, a London, UK-based artificial intelligence (AI)-enabled drug discovery company, raised $6.2M in funding. The company intends to use the funds to demonstrate proof-of-concept for its MOHSAIC platform in diabetic kidney disease. Thus, the above factors are expected to drive the market growth.

Restraint

Limited availability of platforms 

It is expected that the limited availability of massive online data storage and analysis platforms will act as barriers to the expansion of the multi-omics market. The complexity and the lack of skilled professionals in interpreting and implementing the data are also the factors that hamper the market growth. 

Segment Analysis

The global multiomics market is segmented based on type, platform, application, end-user and region.

Single Cell Multiomics segment accounted for 56.7% of the market share 

Single-cell multi-omics technologies often assess numerous types of molecules from a single cell, providing greater in-depth biological knowledge than can be obtained by examining each molecular layer from separate cells.

The increase in the introduction of several platforms for a variety of drug development, research, and clinical trials for novel drug therapies for chronic diseases is expected to hold the segment in the dominant market share. 

For instance, in April 2023, Fulgent Genetics launched the Mission Bio Platform to Broaden the Accessibility of Single-Cell Multi-Omics for Drug Development and Clinical Research.

Additionally, in May 2023, Deepcell launched the REM-I Platform, single cell analysis platform, a high-dimensional cell morphology analysis and sorting platform that comprises the REM-I benchtop instrument, Human Foundation Model, and Axon data suite.

Geographical Analysis

North America is expected to hold a significant position in the global multiomics market share

North America is expected to account for a sizable portion of the worldwide multiomics market during the forecast period. The region's market is expected to increase rapidly owing mostly to the ongoing research initiatives to develop innovative technologies in the region and increased strategies by the major players in developing new platforms for the new studies.

In February 2023, Tempus collaborated with Actuate Therapeutics, Inc. in introducing a brand-new multi-omics. Tempus is implementing a multi-omics approach to this project in which the datasets of different omic groups are combined to improve research and increase novel scientific insights.

Furthermore, In Partnership with 10x Genomics and Olink Proteomics, Psomagen, Inc., at the beginning of 2022 brought end-to-end multiomics solutions to the drug discovery and development, diagnostics, and clinical research industries.

Thus, the above factors along with the increased research activities, increased funding in the region, and the highly advanced technologies in the region are expected to hold the region in the dominant position.

COVID-19 Impact Analysis

COVID-19 has impacted the growth of the market positively. The increase in COVID-19 cases has boosted the research activities through which the mechanism of action of the foreign organism is predicted. Multi-omics has positively impacted a variety of healthcare services. According to healthcare professionals, the multi-omics market is one of the most rapidly evolving markets. Furthermore, the global market is being driven by chronic disorders such as cancer and infectious diseases caused by viruses. The research into multi-omics for COVID-19 could help the target market grow.

Competitive Landscape

The leading companies with a significant market share include Thermo Fisher Scientific Inc., Illumina, Inc., Becton Dickinson, Shimadzu Corporation, Bruker Corporation, QIAGEN, Agilent Technologies, Inc., BGI Genomics, Danaher Corporation, 10x Genomics among others

Key Development

• In September 2023, Bruker introduced novel 4D-Proteomics timsTOF capabilities.
• In February 2023, Becton, Dickinson and Company introduced a new instrument for single-cell multiomics analysis that will enable scientists to run high-throughput studies without sacrificing sample integrity.

Why Purchase the Report?

• To visualize the global multiomics market segmentation based on equipment type, treatment type, end-users, and region as well as understand key commercial assets and players.
• Identify commercial opportunities by analyzing trends and co-development. 
• Excel data sheet with numerous data points of multiomics market-level with all segments.
• PDF report consists of a comprehensive analysis after exhaustive qualitative interviews and an in-depth study.
• Product mapping available as excel consisting of key products of all the major players.

The global multiomics market report would provide approximately 61 tables, 68 figures, and 183 Pages.

Target Audience 2024

• Manufacturers/ Buyers
• Industry Investors/Investment Bankers
• Research Professionals
• Emerging Companies